857 related articles for article (PubMed ID: 15276986)
1. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
Buscaglia C; Nervi P; Risso M
Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
[TBL] [Abstract][Full Text] [Related]
2. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens.
Chang S; Ding Z; Dunn JR; Lee LF; Heidari M; Song J; Ernst CW; Zhang H
Avian Dis; 2011 Sep; 55(3):384-90. PubMed ID: 22017035
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
[TBL] [Abstract][Full Text] [Related]
5. Protection provided by Rispens CVI988 vaccine against Marek's disease virus isolates of different pathotypes and early prediction of vaccine take and MD outcome.
Ralapanawe S; Walkden-Brown SW; Renz KG; Islam AF
Avian Pathol; 2016; 45(1):26-37. PubMed ID: 26503904
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.
Lee LF; Kreager KS; Arango J; Paraguassu A; Beckman B; Zhang H; Fadly A; Lupiani B; Reddy SM
Vaccine; 2010 Feb; 28(5):1294-9. PubMed ID: 19941987
[TBL] [Abstract][Full Text] [Related]
7. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Marek's disease field isolates by the "best fit" pathotyping assay.
Dudnikova E; Norkina S; Vlasov A; Slobodchuk A; Lee LF; Witter RL
Avian Pathol; 2007 Apr; 36(2):135-43. PubMed ID: 17479374
[TBL] [Abstract][Full Text] [Related]
9. Vaccination-challenge interval markedly influences protection provided by Rispens CVI988 vaccine against very virulent Marek's disease virus challenge.
Islam T; Walkden Brown SW; Renz KG; Fakhrul Islam AF; Ralapanawe S
Avian Pathol; 2013 Dec; 42(6):516-26. PubMed ID: 24098951
[TBL] [Abstract][Full Text] [Related]
10. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
Baigent SJ; Smith LP; Nair VK; Currie RJ
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):78-86. PubMed ID: 16682084
[TBL] [Abstract][Full Text] [Related]
11. A deletion in the glycoprotein L (gL) gene of U.S. Marek's disease virus (MDV) field strains is insufficient to confer increased pathogenicity to the bacterial artificial chromosome (BAC)-based strain, RB-1B.
Shaikh SA; Katneni UK; Dong H; Gaddamanugu S; Tavlarides-Hontz P; Jarosinski KW; Osterrieder N; Parcells MS
Avian Dis; 2013 Jun; 57(2 Suppl):509-18. PubMed ID: 23901769
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence.
Shamblin CE; Greene N; Arumugaswami V; Dienglewicz RL; Parcells MS
Vet Microbiol; 2004 Sep; 102(3-4):147-67. PubMed ID: 15327791
[TBL] [Abstract][Full Text] [Related]
13. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease.
Witter RL; Kreager KS
Avian Dis; 2004 Dec; 48(4):768-82. PubMed ID: 15666858
[TBL] [Abstract][Full Text] [Related]
14. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
Karpathy RC; Firth GA; Tannock GA
Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
[TBL] [Abstract][Full Text] [Related]
15. Biocharacteristics shared by highly protective vaccines against Marek's disease.
Gimeno IM; Witter RL; Hunt HD; Reddy SM; Reed WM
Avian Pathol; 2004 Feb; 33(1):59-68. PubMed ID: 14681069
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Marek's disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model.
Baigent SJ; Smith LP; Currie RJ; Nair VK
Avian Pathol; 2007 Dec; 36(6):467-74. PubMed ID: 17994325
[TBL] [Abstract][Full Text] [Related]
17. Protective efficacy of a recombinant bacterial artificial chromosome clone of a very virulent Marek's disease virus containing a reticuloendotheliosis virus long terminal repeat.
Mays JK; Black-Pyrkosz A; Spatz S; Fadly AM; Dunn JR
Avian Pathol; 2016 Dec; 45(6):657-666. PubMed ID: 27258614
[TBL] [Abstract][Full Text] [Related]
18. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus.
Nazerian K; Witter RL; Lee LF; Yanagida N
Avian Dis; 1996; 40(2):368-76. PubMed ID: 8790888
[TBL] [Abstract][Full Text] [Related]
19. Interferon-γ influences immunity elicited by vaccines against very virulent Marek's disease virus.
Haq K; Elawadli I; Parvizi P; Mallick AI; Behboudi S; Sharif S
Antiviral Res; 2011 Jun; 90(3):218-26. PubMed ID: 21501630
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of immunoprotection between vaccination with meq-deleted Marek's disease virus and vaccine strain CVI988/Rispens].
Duan L; Su S; Wang Y; Li S; Sun P; Chen W; Cui Z
Wei Sheng Wu Xue Bao; 2014 Nov; 54(11):1353-61. PubMed ID: 25752142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
